January 22 2020
The NRG Oncology clinical trial GOG-9929 is the first study to describe the safety of immunotherapy following chemoradiotherapy for women with curative cervical cancer. GOG-9929 evaluated 21 women to receive chemoradiotherapy followed by ipilimumab (immunotherapy) at one of two potential dose levels: 3 mg/kg and 10 mg/kg to determine the maximum dose of immunotherapy.
The 12-month progression free survival rate was 81% and the 12-month overall survival rate was 90% with 86% of women finishing 4 cycles of ipilimumab. The maximum tolerated dose of ipilimumab was defined as 10 mg/kg. PD-1 expression increased with chemoradiotherapy treatment and was sustained with immunotherapy.
The results of this trial were reported in JAMA Oncology in November 2019 and were highlighted during the gynecologic session at the American Society for Radiation Oncology’s (ASTRO) Annual Meeting in September 2019. These findings should be taken in consideration when designing future clinical trials for women with node-positive cervical cancer and further research is needed to help identify therapeutic targets to improve outcomes for this patient population.
Read the press release